Seungwoo Chae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seungwoo Chae has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Hahyun An
Department of Food Science and Nutrition, Convergence Program of Material Science for Medicine and Pharmaceutics Hallym University Chuncheon Republic of Korea
2 shared publications - Joan S. Wakefield
University of California, San Francisco and Veterans Affairs Health Care System, San Francisco, United States of America
2 shared publications - Kyong-Oh Shin
Department of Food Science and Nutrition, Convergence Program of Material Science for Medicine and Pharmaceutics Hallym University Chuncheon Republic of Korea
2 shared publications - Kyungho Park
Department of Food Science and Nutrition, Convergence Program of Material Science for Medicine and Pharmaceutics Hallym University Chuncheon Republic of Korea
2 shared publications - Yoshikazu Uchida
Department of Food Science and Nutrition, and Convergence Program of Material Science for Medicine and Pharmaceutics, Hallym University, Chuncheon, Republic of Korea
2 shared publications Anna Celli
Department of Dermatology, School of Medicine, University of California, San Francisco, San Francisco, California, USA; San Francisco VA Medical Center, Northern California Institute for Research and Education, San Francisco, California, USA
1 shared publication
Latest Publications
- Open Access
- 22 July 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (7) , e70121
Small EVs From Adipose‐Derived MSCs Modulate Epidermal Barrier and Inflammation Via Sphingosine‐1‐Phosphate Signaling Pathway
Epidermal permeability barrier defects are associated with several skin diseases, including atopic dermatitis (AD). Using an AD mouse model, we previously demonstrated that topically administered small extracellular vesicles (sEVs) (prepared following the International Society of Extracellular Vesicles recommendations) from human adipose tissue‐derived mesenchymal stem cells (ASC) ameliorate skin inflammation and normalize barrier function in parallel with increased ceramide (a key barrier lipid) production. To elucidate how ASC‐sEVs alleviate these AD skin abnormalities, we characterized lipids and ceramide metabolic enzymes in ASC‐sEVs versus donor ASCs. Our study revealed that free fatty acid, ceramide, and sphingomyelin are enriched in ASC‐sEVs versus donor ASCs, while the synthetic enzymes of ceramide (and acidic sphingomyelinase), and sphingosine‐1‐phosphate (sphingosine kinase) are significantly higher in ASC‐sEVs versus donor ASCs. Conversely, ceramide (ceramidase), and sphingosine‐1‐phosphate hydrolytic enzymes (sphingosine‐1‐phosphate lyase and sphingosine‐1‐phosphate phosphatase) are lower in ASC‐sEVs, suggesting that ceramide and sphingosine‐1‐phosphate levels could elevate in cells that receive ASC‐sEVs. ASC‐sEV‐mediated increases in sphingosine‐1‐phosphate suppress pro‐inflammatory cytokine production in AD‐model human keratinocytes. Additionally, keratinocyte differentiation, which is required for a competent epidermal permeability barrier, was restored in AD‐model human keratinocytes treated with ASC‐sEVs. Taken together, cells that endocytose ASC‐sEVs can normalize epidermal permeability barrier function as well as alleviate inflammation by stimulating a sphingosine‐1‐phosphate signalling pathway.
- 22 July 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (7) , e70121
Open AccessSmall EVs From Adipose‐Derived MSCs Modulate Epidermal Barrier and Inflammation Via Sphingosine‐1‐Phosphate Signaling Pathway
Epidermal permeability barrier defects are associated with several skin diseases, including atopic dermatitis (AD). Using an AD mouse model, we previously demonstrated that topically administered small extracellular vesicles (sEVs) (prepared following the International Society of Extracellular Vesicles recommendations) from human adipose tissue‐derived mesenchymal stem cells (ASC) ameliorate skin inflammation and normalize barrier function in parallel with increased ceramide (a key barrier lipid) production. To elucidate how ASC‐sEVs alleviate these AD skin abnormalities, we characterized lipids and ceramide metabolic enzymes in ASC‐sEVs versus donor ASCs. Our study revealed that free fatty acid, ceramide, and sphingomyelin are enriched in ASC‐sEVs versus donor ASCs, while the synthetic enzymes of ceramide (and acidic sphingomyelinase), and sphingosine‐1‐phosphate (sphingosine kinase) are significantly higher in ASC‐sEVs versus donor ASCs. Conversely, ceramide (ceramidase), and sphingosine‐1‐phosphate hydrolytic enzymes (sphingosine‐1‐phosphate lyase and sphingosine‐1‐phosphate phosphatase) are lower in ASC‐sEVs, suggesting that ceramide and sphingosine‐1‐phosphate levels could elevate in cells that receive ASC‐sEVs. ASC‐sEV‐mediated increases in sphingosine‐1‐phosphate suppress pro‐inflammatory cytokine production in AD‐model human keratinocytes. Additionally, keratinocyte differentiation, which is required for a competent epidermal permeability barrier, was restored in AD‐model human keratinocytes treated with ASC‐sEVs. Taken together, cells that endocytose ASC‐sEVs can normalize epidermal permeability barrier function as well as alleviate inflammation by stimulating a sphingosine‐1‐phosphate signalling pathway.
- 30 August 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (4) , 854-863.e6
Sphingosine-1-Phosphate–Cathelicidin Axis Plays a Pivotal Role in the Development of Cutaneous Squamous Cell Carcinoma
- 30 August 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (4) , 854-863.e6
Sphingosine-1-Phosphate–Cathelicidin Axis Plays a Pivotal Role in the Development of Cutaneous Squamous Cell Carcinoma